---
title: "Tremfya (guselkumab), all indications: Safety questions"
description: "Safety questions on Tremfya (guselkumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings, Infection precautions, and Vaccines. Questions: Does Tremfya increase the risk of infections? Does Tremfya require TB testing before treatment? What are the contraindications for Tremfya? Can Tremfya cause allergic reactions? 2 further questions follow. 6 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/tremfya/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab), all indications: Safety questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)

## Warnings

<a id="tremfya-infections"></a>

### Does Tremfya increase the risk of infections?

> “TREMFYA<sup>®</sup> may increase the risk of infection. Treatment with TREMFYA<sup>®</sup> should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.
>
> Consider the risks and benefits of treatment prior to prescribing TREMFYA<sup>®</sup> in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA<sup>®</sup> to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA<sup>®</sup> until the infection resolves.”

Source: [TREMFYA: Moderate To Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/#:~:text=may%20increase%20the%20risk%20of,until%20the%20infection%20resolves.)

> “Infections occurred in 23% of subjects in the TREMFYA group compared to 
> 21% of subjects in the placebo group through 16 weeks of treatment.
> The most common (≥ 1%) infections that occurred more frequently in the 
> TREMFYA group than in the placebo group were upper respiratory infections, 
> gastroenteritis, tinea infections, and herpes simplex infections; all cases 
> were mild to moderate in severity and did not lead to discontinuation of 
> TREMFYA. The rate of serious infections for the TREMFYA group and the 
> placebo group was ≤ 0.2%.”

Source: [TREMFYA: Prescribing information, page 3, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=3)

<a id="tremfya-contraindications"></a>

### What are the contraindications for Tremfya?

> “TREMFYA<sup>®</sup> is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.”

Source: [TREMFYA: Moderate To Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/#:~:text=is%20contraindicated%20in%20patients%20with,to%20any%20of%20the%20excipients.)

<a id="tremfya-allergic-reactions"></a>

### Can Tremfya cause allergic reactions?

> “Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA<sup>®</sup>. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA<sup>®</sup> and initiate appropriate therapy.”

Source: [TREMFYA: Moderate To Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/#:~:text=Serious%20hypersensitivity%20reactions%2C%20including%20anaphylaxis%2C,and%20initiate%20appropriate%20therapy.)

> “Immune system disorders: Hypersensitivity, including anaphylaxis [see Warnings 
> and Precautions (5.1)]
>
> •	 Skin and subcutaneous tissue disorders: Rash [see Warnings and Precautions (5.1)]”

Source: [TREMFYA: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=5)

<a id="tremfya-labeled-warnings"></a>

### Does Tremfya have labeled warnings for cancer, IBD flares, candidiasis, or MACE?

> “No labeled warnings or precautions for
> malignancy, exacerbation of inflammatory bowel
> disease, candidiasis* or MACE.”

Source: [TREMFYA: Safety In Plaque PsO & Active PsA, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/safety/#safetyconsiderations:~:text=No%20labeled%20warnings%20or%20precautions,disease%2C%20candidiasis%2A%20or%20MACE.)

On the page, select: Safety considerations

> “*Candida infections as adverse reactions occurred in <1% but >0.1% of subjects in the TREMFYA<sup>®</sup> group and at a higher rate than in the placebo group
> through Week 16 in VOYAGE 1 and VOYAGE 2.”

Source: [TREMFYA: Safety In Plaque PsO & Active PsA, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/safety/#safetyconsiderations:~:text=%2ACandida%20infections%20as%20adverse%20reactions,VOYAGE%201%20and%20VOYAGE%202.)

On the page, select: Safety considerations

> “MACE=major adverse cardiovascular event (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke).”

Source: [TREMFYA: Safety In Plaque PsO & Active PsA, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/safety/#safetyconsiderations:~:text=MACE%3Dmajor%20adverse%20cardiovascular%20event%20%28cardiovascular%20death%2C%20nonfatal%20myocardial%20infarction%2C%20and%20nonfatal%20stroke%29.)

On the page, select: Safety considerations

## Infection precautions

<a id="tremfya-tuberculosis"></a>

### Does Tremfya require TB testing before treatment?

> “Evaluate patients for TB infection prior to initiating TREMFYA<sup>®</sup> treatment. Do not administer TREMFYA<sup>®</sup> to patients with active TB infection. Initiate treatment of latent TB prior to administering TREMFYA<sup>®</sup>. Consider anti-TB therapy prior to initiating TREMFYA<sup>®</sup> in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor all patients for signs and symptoms of active TB during and after TREMFYA<sup>®</sup> treatment.”

Source: [TREMFYA: Moderate To Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/#:~:text=Evaluate%20patients%20for%20TB%20infection,treatment.)

## Vaccines

<a id="tremfya-live-vaccines"></a>

### Can patients on Tremfya get live vaccines?

> “Prior to initiating TREMFYA<sup>®</sup>, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA<sup>®</sup>.”

Source: [TREMFYA: Moderate To Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/#:~:text=Immunizations-,Prior%20to%20initiating,vaccines%20in%20patients%20treated%20with)

## Related pages
- [Medical information: Tremfya (guselkumab): All indications](https://www.evicenter.com/medical-information/tremfya)
- [Indication](https://www.evicenter.com/medical-information/tremfya/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/tremfya/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/tremfya/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/tremfya/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/tremfya/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/tremfya/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/tremfya/access-and-coverage)
